Full title: Feasibility of the use of Interactive Technology-enhanced Incentive Spirometry
Aim: assess the usability of InspireVR compared to the currently-used IS device, Spiroball
Background: Patients undergoing major upper gastrointestinal surgery (oesophagectomy or total gastrectomy) are recommended to complete deep breathing exercises, termed incentive spirometry (IS), regularly during their early recovery on the critical care unit in order to reduce the risk of post operative pulmonary complications, such as lung infections. Patients are currently provided with non-electronic devices to guide technique. REVERE Breathe is a mixed-methods, pilot feasibility study evaluating the usability of a novel interactive device, InspireVR. InspireVR has been developed using a human-centred design process to aid patient performance during IS following major upper gastrointestinal surgery. Commercial-off-the-shelf display and interface devices have been combined with novel, purpose-built software providing an IS-based “gameplay”. InspireVR has been designed to remind patients to complete IS (compliance), encourage them to perform the exercises correctly (performance feedback) and record activity for clinician review (activity summary). The primary outcome for the study is the usability of InspireVR compared to the currently-used IS device, Spiroball. All patients undergoing elective oesophagectomy or total gastrectomy at the two recruiting sites over the six month recruitment, Queen Elizabeth Hospital and Heartlands Hospital, will be eligible for recruitment to the trial, up to a total of 25 participants. Trial participation will occur during their post operative admission to critical care, to a maximum of three days. The trial is being carried out to meet the requirements of the MHRA in order to apply as CE mark as a class 1 medical device. Results of REVERE Breathe will inform the development of a randomised controlled trial to evaluate the efficacy of post operative incentive spirometry on development of post operative pulmonary complications.